Guidant shatters Johnson and Johnson stent monopoly in two months
This article was originally published in Clinica
Guidant's ACS Multi-Link stent has gained a 50% share of the US market since its approval in October, with rival company Johnson & Johnson's Palmaz-Schatz stent sales falling considerably, according to one brokerage firm.
You may also be interested in...
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.